TORONTO, ONTARIO–(Marketwire – July 6, 2011) – Arch Biopartners Inc (“Arch” or the “Company”)(CNSX:ACH)(OTC:FOIFF) today announced that the University of Calgary has extended the overhead agreement with its subsidiary Arch Biotech Inc.
(“AB”) and has granted a similar overhead agreement to its subsidiary Arch Cancer Therapeutics Ltd (“ACT”).
Both overhead agreements are valid until July 1, 2012.
About Arch Cancer Therapeutics
ACT is an Alberta corporation wholly owned by Arch. ACT’s objective is to develop non-invasive diagnostic and therapeutic molecules for brain cancer utilizing new and innovative approaches.
About Arch Biotech
AB is an Ontario corporation wholly-owned by Arch and is focused on novel treatments for chronic kidney and bowel diseases caused by non-infectious inflammation.
About Arch Biopartners
Arch Biopartners is a portfolio-based biotechnology company that is developing early stage proprietary technology for sale to pharmaceutical and industrial companies.
The Company’s website address is: www.archbiopartners.com.
For more information on the Company, please consult the other public documents filed on SEDAR at www.sedar.com.
All statements, other than statements of historical fact, in this news release are forward looking statements that involve various risks and uncertainties, including, without limitation, statements regarding the future plans and objectives of the Company. There can be no assurance that such statements will prove to be accurate. Actual results and future events could differ materially from those anticipated in such statements. These and all subsequent written and oral forward-looking statements are based on the estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. The Company assumes no obligation to update forward-looking statements should circumstances or management’s estimates or opinions change.
The CNSX has not reviewed and does not accept responsibility for the adequacy of this press release.